CN101691319A - 一种合成氟代含氮杂环化合物的方法 - Google Patents
一种合成氟代含氮杂环化合物的方法 Download PDFInfo
- Publication number
- CN101691319A CN101691319A CN200910197231A CN200910197231A CN101691319A CN 101691319 A CN101691319 A CN 101691319A CN 200910197231 A CN200910197231 A CN 200910197231A CN 200910197231 A CN200910197231 A CN 200910197231A CN 101691319 A CN101691319 A CN 101691319A
- Authority
- CN
- China
- Prior art keywords
- cdcl
- nmr
- siccative
- product
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Abstract
本发明涉及一种合成氟代含氮杂环化合物的方法,从简单的含氮的烯烃出发,在金属催化下,利用高价的碘化合物为氧化剂,利用无机氟盐为氟源,通过烯烃的氟胺化反应,高选择性的得到含氟的六氢吡啶类化合物。
Description
技术领域
本发明涉及一种合成氟代含氨杂环化合物的方法,是从烯烃制备氟代含氮六元杂环的方法。
背景技术
含氮杂环广泛的用于医药、农药和材料等领域,通过将氟离子的引入医药,农药和生物分子,可以极大地提高药物的活性,提高药效。而在材料分子中引入氟原子,可以极大提高材料的性能。比如,通过SciFinder检索,发现大量专利中描述的药物及其先导化合物中含有氟代含氮杂环。然而,目前合成这样的氟代含氮杂环还是通过经典的氟化反应,比如利用DAST对醇的氟化,但是该反应存在选择性的问题。(SynLett 2007,263;Eur.J.Org.Chem.2007,4224-4234)
发明内容
本发明解决的问题是一种合成氟代含氮杂环化合物的方法,利用无机氟盐,通过对烯烃的双官能化在直接构建杂环分子的同时引入氟原子,高效、高选择性的合成氟代杂环分子。由于使用的无机氟盐,反应中不涉及到有毒的氟化试剂,而且该反应是在常温下进行的,条件非常温和。反应的原料也很容易合成得到,这个反应是以氟化银为氟源,碘苯季戊酸为氧化剂,通过加入催化量的醋酸钯,实现烯烃的胺氟化反应来构建氟代含氮六元杂环。
本发明的典型反应可以用如下反应式表示:
所述的Ph表示苯基,Me表示甲基,Ts表示对甲基苯磺酰基;Ns表示对硝基苯磺酰基。
本发明的底物可以有下面方法得到:(参见文献J.Am.Chem.Soc.,2006,128,4246 4247)。
采用本发明的方法,在室温和腈类溶剂中,存在或不存在干燥剂时,用金属钯盐,三价碘化合物,无机氟盐和烯烃底物反应5-24小时;所述的烯烃底物、金属钯盐、干燥剂、三价碘化合物、无机氟盐的摩尔比为1∶0.01-0.1∶0-100∶1-5∶1-5;反应中加入干燥剂将有助于提高收率。所述干燥剂是硫酸镁、硫酸钠或分子筛等,推荐用量摩尔比为1-10。所述的无机氟盐可以是氟化银、氟化铯或氟氢化钾(KHF2)等。
R=Ts或Ns;Ts表示对甲基苯磺酰基;Ns表示对硝基苯磺酰基。
优选的条件是:0.2mmol底物烯烃,10mol%Pd(OAc)2,200mol%PhI(OCOtBu)2,50mg MgSO4和3当量的AgF,乙腈作为溶剂,在室温下搅拌24小时即可得到产物、其中tBu表示叔丁基。反应完毕后,过滤,固体用二氯甲烷淋洗,合并滤液,浓缩后用硅胶柱层析,得到产品。
采用本发明的方法,可以用较易合成的底物,在温和(室温)的条件下,通过简单的操作,实现氟代含氮六元杂环的合成,步骤简单,选择性好,产率高。
具体实施方式
通过下述实例将有助于本发明,但并不限制本发明的内容。
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃53.4mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到47.9mg产物收率为84%。
1H NMR(400M,CDCl3,TMS),δ7.65(d,J=8.0Hz,2H),7.34(d,J=8.0Hz,2H),4.77(dm,J=47.6Hz,1H),3.61(ddd,J=13.6,11.2,3.6Hz,1H),2.62(ddd,J=11.2,7.6,7.6Hz,1H),2.97(d,J=11.2Hz,1H),2.44(s,3H),2.38(d,J=11.2Hz,1H),1.72(ddd,J=16.8,13.2,4.0Hz,1H),1.35(ddd,J=12.8,12.8,8.8Hz,1H),1.03(d,J=3.6Hz,6H).13C NMR(100M,CDCl3),δ143.66,133.24,129.70,127.45,85.55(d,J=231.9Hz),56.58(d,J=1.5Hz),49.66(d,J=38.0Hz),42.55(d,J=23.6Hz),31.74(d,J=9.9Hz),27.68(d,J=2.4Hz),25.90,21.47.19F NMR(376M,CDCl3),δ-183.16(d,J=45.5Hz).HRMS:m/z(ESI)计算值(calculated)[C14H20F1N1O2S1H+]:286.1272,实测值(measured):286.1276.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,烯烃53.4mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到39mg产物收率为69%。
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃59.7mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到46.8mg产物收率为74%。
1H NMR(400M,CDCl3,TMS),δ8.39(d,J=8.8Hz,2H),7.96(d,J=8.8Hz,2H),4.80(dm,J=47.2Hz,1H),3.56(ddd,J=16.0,11.6,4.0Hz,1H),2.97(d,J=11.6Hz,1H),2.89(ddd,J=11.6,7.6,7.6Hz,1H),2.61(d,J=12.0Hz,1H),1.71(ddd,J=20.4,13.6,4.0Hz,1H),1.46(ddd,J=12.8,12.8,8.0Hz,1H),1.03(s,6H).13C NMR(100M,CDCl3),δ150.18,142.90,128.57,124.36,85.38(d,J=175.5Hz),56.57,49.46(d,J=28.3Hz),42.22(d,J=17.8Hz),31.76(d,J=6.9Hz),27.40(d,J=2.2Hz),26.14.19F NMR(376M,CDCl3),δ-182.60(d,J=42.9Hz).HRMS:m/z(ESI)calculated[C13H17F1N2O4S1Na+]:339.0785,measured:339.0792.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃47.9mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到41.1mg产物收率为80%。
1H NMR(400M,CDCl3,TMS),δ7.66(d,J=8.4Hz,2H),7.33(d,J=8.4Hz,2H),4.67(dm,J=46.8Hz,1H),3.38(ddd,J=18.4,11.6,2.8Hz,1H),3.12(m,1H),2.99(ddd,J=11.2,7.2,7.2Hz,1H),2.89(m,1H),2.44(s,3H),1.85(m,2H),1.63(m,2H).13C NMR(100M,CDCl3),δ143.66,133.31,129.69,127.53,85.68(d,J=175.5Hz),49.57(d,J=27Hz),45.67,29.20(d,J=20.1Hz),21.45,21.08(d,J=6.7Hz).19F NMR(376M,CDCl3),δ-182.72(m).HRMS:m/z(ESI)calculated[C12H16F1N1O2S1H+]:258.0959,measured:258.0962.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃78.3mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到68.0mg产物收率为83%。
1H NMR(400M,CDCl3,TMS),δ7.65(d,J=8.4Hz,2H),7.47(d,J=8.4Hz,2H),7.36-7.12(m,5H),4.55(dm,J=47.2Hz,1H),4.50(d,J=12.4Hz 1H),4.03(m,1H),2.96(m,1H),2.42(s,3H),2.40(d,J=13.2Hz,1H),2.29(ddd,J=10.0,10.0,6.4Hz,1H),2.15(ddd,J=11.2,11.2,11.2Hz,1H).13C NMR(100M,CDCl3),δ145.39,144.06,143.12,132.15,129.89,128.67,128.59,127.75,127.71,126.87,126.51,126.41,85.60(d,J=172.4Hz),53.84,49.82(d,J=30.7Hz),46.44(d,J=10.8Hz),41.05(d,J=19.0Hz),21.53.
19FNMR(376M,CDCl3),δ-185.52(d,J=47.0Hz).HRMS:m/z(ESI)calculated[C24H24F1N1O2S1Na+]:432.1418,measured:432.1404.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmo l)的AgF,100mg的MgSO4以及烯烃50.7mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法依次得到产物cis-product24.1mg和trans-product24.0mg(比例约为1∶1),总收率为89%。Cis-product:1H NMR(400M,CDCl3,TMS),δ7.67(d,J=8.4Hz,2H),7.33(d,J=8.4Hz,2H),4.77(dm,J=46.4Hz,1H),3.89(ddd,J=11.6,11.6,3.2Hz,1H),3.65(dd,J=8.0,1.2Hz),2.58(ddd,J=35.6,13.2,2.0Hz,1H),2.43(s,3H),2.15-1.95(m,3H),1.2-1.0(m,1H),0.89(d,J=6.4Hz,3H).13C NMR(100M,CDCl3),δ143.50,133.77,129.61,127.58,85.22(d,J=175.5Hz),52.08,49.00(d,J=21.5Hz),36.50(d,J=20.8Hz),25.43,21.48,18.46.19FNMR(376M,CDCl3),δ-183.95(dddt,J=10.9,34.6,40.6,75.2Hz).HRMS:m/z(ESI)calculated[C13H18F1N1O2S1H+]:272.1115,measured:272.1121.
Trans-product:1H NMR(400M,CDCl3,TMS),δ7.65(d,J=8.0Hz,2H),7.34(d,J=8.0Hz,2H),4.62(dm,J=48.4Hz,1H),4.03(m,1H),3.64(m,1H),2.45(s,3H),2.20-2.12(m,2H),1.88-1.78(m,2H),1.00(m,1H),0.94(d,J=6.4Hz,3H).13C NMR(100M,CDCl3),δ143.81,133.12,129.78,127.55,86.92(d,J=174.5Hz),52.20(d,J=1.5Hz),49.40(d,J=31.1Hz),38.80(d,J=17.4Hz),29.08(d,J=10.6Hz),21.52,18.38.19F NMR(376M,CDCl3),δ-180.80(d,J=44.0Hz).HRMS:m/z(ESI)calculated[C13H18F1N1O2S1H+]:272.1115,measured:272.1125.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃63.1mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法依次得到产物cis-product18.3mg和t rans-product18.4mg(比例约为1∶1),总收率为55%。
Cis-product:1H NMR(400M,CDCl3,TMS),δ7.67(d,J=8.4Hz,2H),7.35-7.14(m,7H),4.90(dm,J=46.8Hz,1H),4.13(m,1H),3.92(m,1H),3.25(m,1H),2.62(ddd,J=37.6,13.2,1.6Hz,1H),2.43(s,3H),2.42(m,1H),2.24(m,1H),1.70(m,1H).13C NMR(100M,CDCl 3),δ143.64,141.17,133.80,129.69,128.76,127.65,127.26,127.10,85.01(d,J=166.9Hz),51.57,48.90(d,J=21.5Hz),36.15,34.95(d,J=21.6Hz),21.53.19F NMR(376M,CDCl3),δ-184.50(dddt,J=10.9,38.0,41.7,79.7Hz).HRMS:m/z(ESI)calculated[C18H20F1N1O2S1H+]:334.122,measured:334.1274.
Trans-product:1H NMR(400M,CDCl3,TMS),δ7.64(d,J=8.0Hz,2H),7.36-7.15(m,7H),4.78(dm,J=48.4Hz,1H),4.20(m,1H),3.87(m,1H),2.96(m,1H),2.44(s,3H),2.40(m,1H),2.25(ddd,J=10.4,10.4,4.0Hz,1H),2.15(dd,J=10.4,10.4Hz,1H),1.64(m,1H).13C NMR(100M,CDCl3),δ143.96,140.14,133.09,129.85,128.82,127.57,127.46,127.10,86.92(d,J=175.5Hz),52.00,49.50(d,J=31.5Hz),40.06(d,J=10.4Hz),36.95(d,J=18.6Hz),31.57,27.05,21.53.19F NMR(376M,CDCl3),δ-181.2(dm,J=47.4Hz).HRMS:m/z(ESI)calculated[C18H20F1N1O2S1H+]:334.1272,measured:334.1275.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃58.7mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法依次得到产物cis-product40.6mg和trans-product13.5mg(比例为3∶1),总收率为87%。
Cis-product:1H NMR(400M,CDCl3,TMS),δ7.73(d,J=8.4Hz,2H),7.28(d,J=8.4Hz,2H),4.75(dm,J=49.2Hz,1H),4.03(m,1H),3.28(ddd,J=24.4,14.4,3.6Hz,1H),2.75(ddd,J=10.8,10.8,3.6Hz,1H),2.43(s,3H),2.25(m,1H),1.86(m,1H),1.80-1.62(m,4H)1.43(m,1H),1.30-1.10(m,3H),0.96(m,1H).13C NMR(100M,CDCl3),δ143.13,138.25,129.57,127.02,85.70(d,J=174.9Hz),63.57,48.45(d,J=25.3Hz),36.01(d,J=21.5Hz),35.54,32.64,31.39,25.61,25.24,21.44.19F NMR(376M,CDCl3),δ-180.90(dddt,J=13.1,17.6,38.0,66.6Hz).HRMS:m/z(ESI)calculated[C16H22F1N1O2S1Na+]:334.1248,measured:334.1261.
Trans-product:1H NMR(400M,CDCl3,TMS),δ7.67(d,J=8.0Hz,2H),7.30(d,J=8.0Hz,2H),4.68(dm,J=44.4Hz,1H),4.28(m,1H),2.86(ddd,J=12.4,8.4,6.8Hz,1H),2.45(m,1H),2.43(s,3H),2.20(m,1H),2.10(m,1H),1.84-1.36(m,5H),1.22-1.00(m,4H).13C NMR(100M,CDCl3),δ143.26,137.24,129.59,127.21,87.30(d,J=176.0Hz),64.20,51.50(d,J=29.6Hz),39.13(d,J=9.1Hz),38.10(d,J=17.5Hz),33.03,31.11,25.69,25.08,21.50.19FNMR(376M,CDCl3),δ-175.15(dm,J=50.7Hz).HRMS:m/z(ESI)calculated[C16H22F1N1O2S1H+]:312.1428,measured:312.1430.
将4.5mg(0.02mmol)的Pd(OAc)2,162.5mg(0.4mmol)的PhI(OCOtBu)2,125.9mg(1.0mmol)的AgF,100mg的MgSO4以及烯烃56.3mg(0.2mmol)加入反应管中,然后加入1ml无水乙腈,在室温下搅拌24小时。然后过滤,固体用二氯甲烷洗,合并滤液,浓缩,柱层析,用乙酸乙酯和石油醚梯度淋洗法得到产物34.7mg和(两产物无法分开比例为5∶1),总收率为55%。
major:1H NMR(400M,CDCl3,TMS),δ7.66(d,J=8.0Hz,2H),7.31(d,J=8.0Hz,2H),4.85(dm,J=46.8Hz,1H),3.62(ddd,J=18.4,14.4,6.4Hz,1H),3.10(d,J=14.4Hz,1H),3.03(ddd,J=19.6,14.0,6.4Hz,1H),2.72(d,J=14.4Hz,1H),2.43(s,3H),2.05-1.82(m,2H),140-1.20(m,2H),1.03(s,3H),0.96(s,3H).13C NMR(100M,CDCl3),δ143.44,133.59,129.73,127.18,90.80(d,J=170.6Hz),61.59,54.50(d,J=31.1Hz),34.39,33.73(d,J=6.8Hz),27.83,27.50(d,J=20.4Hz),26.36,21.49.19F NMR(376M,CDCl3),δ-174.22(ddt,J=16.5,45.1,62.4Hz).4m-minor:1H NMR(400M,CDCl3,TMS),δ7.69(d,J=8.0Hz,2H),7.29(d,J=8.0Hz,2H),4.40(dm,J=46.4Hz,1H),4.33(m,1H),4.26(m,1H),3.35(m,1H),3.23(m,1H),2.42(s,3H),1.45-1.30(m,2H),1.23-1.10(m,2H),0.90(s,3H),0.88(s,3H).13C NMR(100M,CDCl3),δ143.04,135.58,129.50,127.04,81.43(d,J=173.7Hz),52.17,50.84(d,J=21.3Hz),41.98,32.51,30.16,28.77,23.20.19F NMR (376M,CDCl3),δ-223.52(dt,J=19.2,48.5Hz).
HRMS:m/z(ESI)calculated[C15H22F1N1O2S1H+]:300.1428,measured:300.1419.
Claims (9)
1.一种合成氟代含氮的杂环化合物的方法,其特征是在室温、腈类溶剂中以及存在或不存在干燥剂时,用金属钯盐,三价碘化合物,无机氟盐和烯烃底物反应5-24小时;所述的烯烃底物、金属钯盐、三价碘化合物、干燥剂、无机氟盐的摩尔比为1∶0.01-0.1∶1-5∶0-100∶1-5;所述的烯烃底物为1)其中R1=H、Ph或Me,R2=H、Ph或Me,R=Ts或Ns;所述的Ts表示对甲基苯磺酰基;Ns表示对硝基苯磺酰基。
2.根据权利要求1所述的方法,其特征是所述的金属钯盐为醋酸钯、氯化钯或三氟醋酸钯。
3.根据权利要求1所述的方法,其特征是所述的三价碘是碘苯醋酸、碘苯季戊酸或碘苯苯甲酸。
4.根据权利要求1所述的方法,其特征是所述的腈类溶剂是乙腈、丙腈或苯甲腈,它们经过CaH2干燥处理。
5.根据权利要求1所述的方法,其特征是所述的烯烃底物、金属钯盐、三价碘化合物、干燥剂、无机氟盐的摩尔比为1∶0.01-0.1∶1-5∶1-10。
6.根据权利要求1所述的方法,其特征是所述的干燥剂是硫酸镁、硫酸钠或分子筛。
7.根据权利要求1所述的方法,其特征是所述的无机氟盐是氟化银、氟化铯或氟氢化钾。
8.根据权利要求1所述的方法,其特征是反应结束后产物经过过滤除去不溶物,溶剂洗涤,浓缩和柱层析分离。
9.根据权利要求1所述的方法,其特征是反应产物是氟代的单环和双环的含氮杂环。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910197231A CN101691319B (zh) | 2009-10-15 | 2009-10-15 | 一种合成氟代含氮杂环化合物的方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200910197231A CN101691319B (zh) | 2009-10-15 | 2009-10-15 | 一种合成氟代含氮杂环化合物的方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101691319A true CN101691319A (zh) | 2010-04-07 |
CN101691319B CN101691319B (zh) | 2012-10-10 |
Family
ID=42080056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200910197231A Expired - Fee Related CN101691319B (zh) | 2009-10-15 | 2009-10-15 | 一种合成氟代含氮杂环化合物的方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101691319B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146388A (zh) * | 2016-07-05 | 2016-11-23 | 山东理工大学 | 一种3‑苯基‑哌啶类衍生物合成方法 |
CN116283672A (zh) * | 2023-03-27 | 2023-06-23 | 四川师范大学 | 一种β-烯丙基苯乙胺衍生物的合成方法及应用 |
-
2009
- 2009-10-15 CN CN200910197231A patent/CN101691319B/zh not_active Expired - Fee Related
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106146388A (zh) * | 2016-07-05 | 2016-11-23 | 山东理工大学 | 一种3‑苯基‑哌啶类衍生物合成方法 |
CN106146388B (zh) * | 2016-07-05 | 2018-12-04 | 山东理工大学 | 一种3-苯基-哌啶类衍生物合成方法 |
CN116283672A (zh) * | 2023-03-27 | 2023-06-23 | 四川师范大学 | 一种β-烯丙基苯乙胺衍生物的合成方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101691319B (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Cong et al. | Role of mono-N-protected amino acid ligands in palladium (II)-catalyzed dehydrogenative Heck reactions of electron-deficient (hetero) arenes: Experimental and computational studies | |
Fuchibe et al. | NHC-catalyzed generation of difluorocarbene and its application to difluoromethylation of oxygen nucleophiles | |
KR100283066B1 (ko) | 비페닐 유도체를 제조하는 방법 | |
Shakhmaev et al. | Stereoselective synthesis of allylamines by iron-catalyzed cross-coupling of 3-chloroprop-2-en-1-amines with grignard reagents. Synthesis of naftifine | |
CN114456121A (zh) | 一种1,2,4-三氮唑衍生物的合成方法 | |
García-Muñoz et al. | Base-promoted diastereoselective addition of nitromethane and nitroethane to N-tert-butylsulfinyl imines: synthesis of N-protected α-amino acids and amino ketones | |
CN101691319B (zh) | 一种合成氟代含氮杂环化合物的方法 | |
Zupan et al. | Preparation of a polymer-supported aryliodine (III) difluoride and its use to fluorinate olefins to difluorides | |
CN109942616A (zh) | 一种含炔基的芳基酰胺类衍生物及其制备方法和应用 | |
US10087126B2 (en) | Process for the preparation of halo-substituted benzenes | |
JP6548214B2 (ja) | アミノサリチルアルジミン配位子を金属に配位させた触媒及びこれを用いたヨード環化体の製造方法 | |
CN110204474A (zh) | 一种合成对四取代nh-吡咯类化合物的方法 | |
CN103910618B (zh) | 一种2-氟代芳基羰基化合物的合成方法 | |
US8530666B2 (en) | Copper-catalysed process for the production of substituted or unsubstituted trifluormethylated aryl and heteroaryl compounds | |
Dolensky et al. | New building blocks for fluorinated bioimidazole derivatives II: preparation of β-fluorourocanic acids | |
CN105669583A (zh) | 一种高区域与高立体选择性合成(Z)-α/β-氟代烯酰胺的方法 | |
CN113896662A (zh) | 一种氨基环丙烷羧酸类化合物及其制备方法和应用 | |
US11021421B2 (en) | Preparing unsaturated carbocyclic compounds | |
JP5853772B2 (ja) | α,α−ジフルオロ芳香族化合物の製造方法 | |
CN105130873A (zh) | 3-二氟烷基取代的氨基氧化吲哚衍生物及其合成方法 | |
CN104447439B (zh) | 一种具有光学活性的含氟烷基烯丙基胺类化合物及制备方法 | |
CN106316894A (zh) | 一种硝基丙烯酰胺类化合物的合成方法 | |
KR20090113979A (ko) | 4-클로로메틸-비페닐 유도체의 제조 방법 | |
CN1285576C (zh) | 2-三氟甲基吲哚的合成方法 | |
KR101427014B1 (ko) | 아릴, 헤테로아릴 혹은 알케닐 치환 불포화 탄화수소류의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20121010 Termination date: 20171015 |